American scientists found inhaling xenon boosted brain health and improved problem-solving skills, which could potentially ...

American scientists found inhaling xenon boosted brain health and improved problem-solving skills, which could potentially ...

And though drugs that have some effect on Alzheimer’s disease, dementia’s most common manifestation, have recently been ...

The FDA has accepted Eisai and Biogen’s biologics license application for a monthly infusion of IV Leqembi to treat ...

The Alzheimer's Accountability and Investment Act (Public Law 118-93), enacted on October 1, 2024, mandates that the National ...

The Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for subcutaneous (SC) maintenance dosing of lecanemab-irmb for the treatment of Alzheimer disease (AD) in ...

The finding has implications for all of us, write Harvard physician-researchers Christopher Worsham and Anupam Jena.

Leqembi's subcutaneous dosing allows Alzheimer's patients to administer weekly treatment at home in 15 seconds. Get Real-Time ...

The lifetime risk of dementia after age 55 is about 42% - more than double the risk reported by earlier studies, and one that puts greater urgency on the need to mitigate addressable health problems, ...

In a simulated trial, the Florey Dementia Index achieved mean absolute errors of 1.57 and 0.70 years for predicting mild cognitive impairment and Alzheimer's disease onset, respectively ...

The number of US adults who will develop dementia each year is projected to increase from approximately 514,000 in 2020 to ...